

Predictive modeling of the human hepatoma (Huh-7D12) cancer line of a series of bis- (5-arylidene-rhodanine-3-yl) diamine.

Abstract

This work deals with the prediction of the antiproliferative activity of eighteen (18) substances derived from bis-5-arylidene rhodanine against human hepatoma tumor line (Huh-7D12). while applying the functional density theory (DFT) method to the B3LYP / 6-31G (d, p) level, theoretical descriptors were determined and correlated with antiproliferative (Huh-7) activity by linear regression multiple (RML). This correlation has shown that the electron energy, the energy of the lowest vacant molecular orbital (E_{LUMO}) and the molecular volume (VM) are the quantum and geometric descriptors that best influences the antiproliferative activity of the molecules studied. The coefficient of determination R^2 indicates that 97.9% of the molecular descriptors defining this model are taken into account with a standard deviation of 0.015. The significance of the model reflected by the Fischer test is estimated at 123.648. The robustness of the model given by the cross-validation correlation coefficient (Q^2_{CV}) is 97.9%. This model has been validated by Tropsha criteria. The very good correlation between these three descriptors and the Huh-7 activity was confirmed by the nonlinear multiple regression (RNML) method with better statistical data. ($R^2 = 0,998$; $Q^2_{CV} = 0,998$; $RMSE = 0,006$).

Mots clés : RML, RMNL, Huh-7D12, bis-5-arylidène rhodanine, Molecular Descriptors.

1. Introduction

The liver is an organ of the digestive system that ensures a particular role of purification of the body. It is also a key organ of body to eliminate toxic compounds. Several types of tumors can develop in this organ, the most common form is hepatocellular carcinoma (or hepatocarcinoma). Hepatocellular carcinoma (HCC) is the most common primary liver tumor in the world. The incidence is globally eleven (11) out of one hundred thousand men (100,000) and 1.5 out of 100,000 women [1], and accounts for about 500,000 deaths, the third leading cause of cancer deaths [2]. Surgery, chemotherapy and irradiation are the main therapeutic approaches to cancer, chemotherapy being an important part of the treatment of cancer patients. However, its success is limited due to the lack of selectivity of tumor cells over normal cells, resulting in insufficient drug concentrations in tumors, systemic toxicity, and the appearance of drug-resistant tumor cells [3]. Targeted molecular therapy can cause less damage to normal cells and may have fewer side effects than other types of cancer treatment. It therefore gains importance because of their specificity with respect to cancer cells, while sparing their toxicity for non-targeted cells. It is in this context that Coulibaly et al [4] synthesized a series of bis-5-arylidene rhodanine derivatives to evaluate their potential as anticancer agents. The in vitro antiproliferative activity of synthesized bis-5-arylidene rhodanine has been studied on the human hepatoma (liver) cancer cell line (Huh-7D12). These compounds, which are very active against the Huh-7D12 line, represent a promising starting point for the development of new, more potent anticancer agents in the future. In this context, the study of Quantitative Structure-Activity Relation (QSAR) is well adapted. The remarkable advances known in the development of computer tools and techniques are of considerable help to the use of this science. This study is a highly sought-after technique because it favors the reduction of the number of experiences that are often long, dangerous and costly in terms of time and finance [5–8]. The descriptors are determined by the methods of quantum chemistry. This QSAR study has its origins in the studies carried out by Hansch [9] and by Free and Wilson [10]. Indeed, Hansch has established models relating biological activity with the hydrophobic, electronic and steric properties of molecules. In general, the QSAR model is based on a fifth (1/5) of the initial database. The QSAR model is a mathematical relation that allows to correlate quantitatively the Huh-7D12 line of the series of molecules and their physicochemical properties (descriptors). In this work, the main goal is to apply

48 QSAR modeling to develop robust and reliable models capable of predicting the antiproliferative
 49 activity of a series of twenty (18) bis-5-arylidene rhodanine derivatives against the tumor line of human
 50 hepatoma (Huh-7D12).

51 2. Material and methods









52 2.1. Materials and Method of Calculation











53 Eighteen (18) molecules of bis-5-arylidene rhodanine derivatives were used in this study (Table 1).
 54 Their minimum inhibitory concentration (**IC₅₀**) varies between 75 and 133 μM . The minimum
 55 inhibitory concentration (**IC₅₀**) is the lowest concentration required to achieve an antiproliferative
 56 response. Biological data is usually expressed as the opposite of the log 10 activity base ($-\log_{10}(C)$) to
 57 obtain higher mathematical values when the structures are biologically very efficient [11; 12]. The
 58 antiproliferative activity is expressed by the antiproliferative potential **pIC₅₀** which is calculated from
 59 the following equation (1):

$$PIC_{50} = -\log_{10}(IC_{50} * 10^{-6}) \quad (1)$$

60 Where **IC₅₀** represents the median inhibitory concentration of a drug required for 50% inhibition in
 61 vitro.

62 **Tableau 1** : molecular structure and antiproliferative activity of the eighteen molecules used.

Code	Molecules	IC ₅₀ (μM)	Code	Molecules	IC ₅₀ (μM)
R1		91	R10		100
R2		114	R11		118
R3		117	R12		75
R4		113	R13		117

R5		121	R14		109
R6		133	R15		122
R7		106	R16		111
R8		130	R17		110
R9		108	R18		104

63

2.2. Calculation Level

64 The relationship between the values of the biological activity of the studied molecules and their
 65 molecular structures was established thanks to the quantum chemistry calculations realized with the
 66 Gaussian software 09[13]. Calculations were performed using the Functional Density Theory (DFT)
 67 method, which is known to generate a variety of molecular properties [14–17] in QSAR studies that
 68 increases predictability, reduces computational time, and influences cost of designing new drugs [11;
 69 18]. The theoretical level of B3LYP / 6-31G (d, p) was used to determine the molecular descriptors. The
 70 modeling was carried out using the multilinear regression method implemented in Excel tables [19] and
 71 XLSTAT [20].

72

2.3. Quantum Descriptors

73 In order to develop a QSAR model, some descriptors of the DFT have been determined. In particular the
 74 electronic energy (E) which represents the electronic contribution of all of the atoms of each molecule
 75 and the energy of the lowest vacant orbital (E_{LUMO}). These energies were calculated as part of
 76 Koopmans' approximation [21]. We have also calculated the molecular volume, which is a geometric

77 descriptor thanks to the software molinspiration [22]. The molecular volume is the volume occupied by
78 the molecule and is generally expressed in cubic Angstroms (A^3) [23; 24].
79 For all the descriptors studied, the analysis of the bivariate data, that is to say the calculation of the
80 linear correlation coefficient R between each pair of the set of descriptors, is less than 0.95 ($R < 0.95$),
81 which means that these different descriptors are independent of each other [25; 26; 11].

82 2.4. Régressions Multiple Linéaires et non Linéaire (RML et RMNL)

83 The Multiple Linear Regression (RML) statistical method is one of the most popular modeling methods
84 due to its ease of use and ease of interpretation. It has been used to study the relationship between
85 biological activity (dependent variable) and theoretical descriptors (independent variables) [27]. RML
86 minimizes differences between actual and expected values. The advantage of RML is that it is very
87 transparent, since the algorithm is available, and that predictions can be made easily [28]. The RML
88 method is based on the assumption that the property depends linearly on the different variables (the
89 descriptors), according to the relation:

$$Y = a_0 + \sum_{i=1}^n a_i X_i \quad (6)$$

90 With: Y is the dependent variable (to explain or predict); X_i : the independent (explanatory) variables; n
91 is the number of explanatory variables; a_0 is the constant of the equation of the model; a_i : descriptor
92 coefficients in the model equation.

93 This method was also used for the selection of molecular descriptors used in multiple nonlinear
94 regression (RMNL). Multiple linear and nonlinear regressions were used to predict the effects on the
95 activity of bis-5-arylidene rhodanine derivatives on Huh-7D12 cancer cells. Multiple nonlinear
96 regression is a nonlinear method (exponential, logarithmic, polynomial, ...) which makes it possible to
97 determine the mathematical model making it possible to explain nonlinearly as well as possible the
98 variability of a property or activity Y according to molecular descriptors X. In all our work we have
99 used the polynomial model based on the descriptors proposed by the linear model which will be raised
100 to the power 2 according to the following equation:

$$Y = a_0 + \sum_{i=1}^n a_i X_i + b_i X_i^2 \quad (7)$$

101 With: Y is the dependent variable (to explain or predict); X_i : the independent (explanatory) variables; n
102 is the number of explanatory variables; a_0 is the constant of the equation of the model; a_i and b_i :
103 descriptor coefficients in the model equation.

104 RML and RMNL were generated using the XLSTAT software version 2016 [29] to predict the
105 anticancer activity IC_{50} . The equations of the different models were evaluated by the coefficient of
106 determination (R^2) which measures the adequacy of the model and the predictive power of the QSAR
107 model; the Root Mean Square Error (RMSE) which must be less than 10% of the range of the target
108 property value [30]; the Fischer test (F) Test F, for the statistical significance of the model (higher is
109 high, the better is the same set of descriptors and chemicals) [31] and the cross correlation coefficient
110 (Q_{cv}^2) which allows for evaluate the predictive power associated with a QSAR model ($Q_{cv}^2 > 0,6$ for a
111 satisfactory model while for an excellent model $Q_{cv}^2 > 0,9$) [32]. These different statistical parameters
112 are given by the following expressions:

$$R^2 = 1 - \frac{\sum (y_{i,exp} - \hat{y}_{i,theo})^2}{\sum (y_{i,exp} - \bar{y}_{i,exp})^2} \quad (2)$$


E_{LUMO} (eV)	1		
E (eV)	-0.585	1	
VM(A ³)	0.812	-0.928	1

141 The linear correlation coefficients R calculated from the series of descriptors are less than 0.95 (R
 142 <0.95). This reflects the non-dependence of the descriptors used to develop the models. The correlation
 143 between the experimental IC50 inhibition concentrations and the theoretical descriptors of the studied
 144 molecules is presented below. Figure 1 represents the correlation between the experimental activities
 145 and the theoretical activities predicted by the model. The negative or positive sign of the coefficient of a
 146 descriptor of the model reflects the effect of proportionality between the evolution of the biological
 147 activity and this parameter of the regression equation. The negative sign indicates that when the value of
 148 the descriptor is high, the biological activity decreases. The positive sign reflects the opposite effect.
 149 The equation obtained is shown below:


$$150 \quad pIC_{50}^{exp} = 7.454 + 1.0392 * ELUMO - 7.4381.10 - 06 * E - 2.9477.10 - 03 * VM$$

$$151 \quad N=12 \quad R^2 = 0.979 \quad Q^2_{CV} = 0.979 \quad RMSE = 0.015 \quad F = 123.648 \quad R^2 - Q^2_{CV} = 0.00$$

152 This model indicates that HOMO energy, electron energy and molecular volume explain to about 98%
 153 ($R^2 = 0.979$) the variability of experimental anticancer activity. The negative signs of the coefficients of
 154 the electronic energy (E) and the molecular volume (VM), indicate that the anticancer activity will be
 155 improved for low values of these descriptors. And the positive sign of the energy of the lowest vacant
 156 orbital (E_{LUMO}) also indicates that anticancer activity will be improved for high values of this energy.
 157 The meaning of the model is expressed by the Fischer coefficient $F = 123.648$: the correlation
 158 coefficient of the cross validation $Q^2_{CV} = 0.979$ reflects an excellent robustness of the model ($Q^2_{CV} >$
 159 0.9). This model is acceptable with $R^2 - Q^2_{CV} = 0,979 - 0,979 = 0,000 < 0,3$.



160
 161 **Figure 1:** Regression line of the obtained RML model



162
 163
 164
 165
 166
 167
 168 **Figure 2:** Similarity curve of the experimental and predicted values of the RML model

169
 170

171 3.1.1. Verification of Tropsha Criteria

172 The results of the calculation of the Tropsha criteria of the RML model are as follows:

$$173 R_{Test}^2 = 0.987 > 0.7 \quad Q_{CV\ Test}^2 = 0.987 > 0.6 \quad |R_{Test}^2 - R_0^2| = 0.0128 \leq 0.3$$


$$174 \frac{|R_{Test}^2 - R_0^2|}{R_{Test}^2} = 0.0130 < 0,1 \text{ and } 0.85 \leq k = 1.00 \leq 1.15 ;$$

$$175 \frac{|R_{Test}^2 - R_0^2|}{R_{Test}^2} = 0.0130 < 0,1 \text{ and } 0.85 \leq k' = 1.00 \leq 1.15$$

176 The model is therefore acceptable for predicting Huh7 anticancer activity because it meets the five
177 criteria of Tropsha [34–36].

178 3.1.2. Analysis of the contribution of the descriptors

179 The study of the contribution of the descriptors relating to the prediction of the antiproliferative activity
180 of the compounds was carried out for cancer cells of the human liver (Huh-7D12). This contribution of
181 the three descriptors in the prediction of the antiproliferative activity of the bis-5-arylidene rhodanine
182 derivatives was determined from the XLSTAT software version 2016[20]. The different contributions are
183 illustrated in Figure 3.



184

185 **Figure 3:** Contribution of descriptors in the RML model

186 The decreasing order of the contribution of different descriptors in the prediction of the antiproliferative
187 activity of Huh-7D12 is: $VM > E > E_{LUMO}$. According to this sequence, the molecular volume is the
188 priority descriptor followed by the electronic energy and finally the energy of the lowest molecular orbital
189 vacant.

190 3.2. NonLinear Multiple Regression (RMNL)


191 The statistical nonlinear regression method was used to improve the anticancer activity of the
192 compounds predicted quantitatively. It takes into account the three chosen descriptors (E_{LUMO} , E , VM).
193 It is the most common tool for studying multidimensional data. This statistical method is applied to the
194 data in Tables 3. The result obtained is the following:

$$195 \text{pIC}_{50}^{exp} = 48.0625 + 30,8771 * E_{LUMO} + 5.4404 \cdot 10^{-05} * E + 4.5621 \cdot 10^{-03} * VM + 5.5441 * E_{LUMO}^2 +$$
$$196 4.3026 \cdot 10^{-10} * E^2 - 8.4391 \cdot 10^{-06} * VM^2$$

$$197 N = 12 \quad R^2 = 0.998 \quad Q_{CV}^2 = 0.998 \quad RMSE = 0.006 \quad R^2 - Q_{CV}^2 = 0.00$$

198 In this model, the descriptors (E_{LUMO} , E , VM) used, express the variability of the anticancer activity to a
199 little more than 99%. The correlation coefficient of the cross validation $Q_{CV}^2 = 0.998$ which shows the
200 very good robustness of the model ($Q_{CV}^2 > 0.9$). This model is acceptable with $R^2 - Q_{CV}^2 = 0.998 -$


201 **0.998 = 0.000 < 0.3**. The regression line between the experimental and theoretical anticancer
 202 activities of the test set (blue dots) and the test set (red dots) is shown in Figure 4.



203

204

Figure 4: The regression line of the RMNL model



205

206

Figure 5: Similarity curve of the RMNL model

207 For RMNL models, the very low value of the standard error (**RMSE = 0,006**) also demonstrates the
 208 good similarity between predicted and experimental values (Figure 5). This curve shows a very good
 209 evolution between the experimental values and predicted by the RMNL model of the anticancer activity
 210 of the rhodanine derivatives studied.

211 **Table 4:** Values of the theoretical activity / experimental activity ratio of the validation set of the two
 212 models.

<i>Model RMNL</i>			
Compounds	pCI ₅₀ exp	pCI ₅₀ pred	pCI ₅₀ pred/ pCI ₅₀ exp
R2	3.928	3.928	1.00
R5	3.959	3.959	1.00
R10	3.975	3.975	1.00
R17	3.928	3.928	1.00
R14	3.963	3.963	1.00
R16	3.955	3.955	1.00

213 All values in the pCI₅₀pred / pCI₅₀exp report tend to 1 (Table 4). This indicates a good correlation
 214 between the theoretical and experimental toxicity of the rhodanines studied. This model is acceptable
 215 for predicting the toxicity of rhodanines on the human hepatoma line (Huh-7D12).

216

4. Conclusion

217 The electron energy, the highest occupied orbital energy (E_{HOMO}) and the molecular volume (VM) have
 218 been used to describe and predict the activity of 18 molecules derived from bis-5-arylidene rhodanine

219 against the cancer line. of human hepatoma (Huh-7D12). Multiple linear regression was used to quantify
220 the relationships between molecular descriptors and the properties of the antiproliferative activity of bis-
221 5-arylidene rhodanine derivatives. This study revealed a strong correlation between the experimental
222 antiproliferative activities and the theoretical descriptors calculated by DFT. In addition, the good
223 correlation between the Huh-7D12 activity and these three descriptors was confirmed by the nonlinear
224 multiple regression method. The molecular volume appears as the priority descriptor.

225 References

- 226 [1] L. Fartoux, C. Desbois-Mouthon and O. Rosmorduc, *Carcinome hépatocellulaire*, EMC-Hépatologie (2009),
227 7–38.
- 228 [2] D.M. Parkin, F. Bray, J. Ferlay and P. Pisani, *Global cancer statistics, 2002*, CA: a cancer journal for
229 clinicians, 55 (2) (2005), 74–108.
- 230 [3] G. Xu and H.L. McLeod, *Strategies for enzyme/prodrug cancer therapy*, *Clinical Cancer Research*, 7 (11)
231 (2001), 3314–3324.
- 232 [4] W. Coulibaly, L. Paquin, A. Béné, Y.-A. Bekro, E. Durieux, L. Meijer, R. Le Guével, A. Corlu and J.-P.
233 Bazureau, *Synthesis of New N, N'-Bis (5-arylidene-4-oxo-4, 5-dihydrothiazolin-2-yl) piperazine Derivatives*
234 *Under Microwave Irradiation and Preliminary Biological Evaluation*, *Scientia pharmaceutica*, 80 (4) (2012),
235 825–836.
- 236 [5] D. Soro, L. Ekou, M.G.-R. Koné, T. Ekou, S.T. Affi, L. Ouattara and N. Ziao, *Prediction of the Inhibitory*
237 *Concentration of Hydroxamic Acids by DFT-QSAR Models on Histone Deacetylase 1*, *International*
238 *Research Journal of Pure and Applied Chemistry* (2018), 1–13.
- 239 [6] A. Tropsha, *Best practices for QSAR model development, validation, and exploitation*, *Molecular*
240 *informatics*, 29 (6-7) (2010), 476–488.
- 241 [7] M.T. Chhabria, B.M. Mahajan and P.S. Brahmshatriya, *QSAR study of a series of acyl coenzyme A (CoA)*,
242 *Medicinal Chemistry Research*, 20 (9) (2011), 1573–1580.
- 243 [8] V.M. Buha, D.N. Rana, M.T. Chhabria, K.H. Chikhalia, B.M. Mahajan, P.S. Brahmshatriya and N.K. Shah,
244 *Synthesis, biological evaluation and QSAR study of a series of substituted quinazolines as antimicrobial*
245 *agents*, *Medicinal Chemistry Research*, 22 (9) (2013), 4096–4109.
- 246 [9] C. Hansch and T. Fujita, *p - σ - π Analysis. A Method for the Correlation of Biological Activity and Chemical*
247 *Structure*, *J. Am. Chem. Soc.*, 86 (8) (1964), 1616–1626.
- 248 [10] S.M. Free and J.W. Wilson, *A Mathematical Contribution to Structure-Activity Studies*, *J. Med. Chem.*, 7 (4)
249 (1964), 395–399.
- 250 [11] N.J.-B. Kangah, M.G.-R. Koné, A.L.C. Kablan, S.A. Yéo and N. Ziao, *Antibacterial Activity of Schiff Bases*
251 *Derived from Ortho-Diaminocyclohexane, Meta-Phenylenediamine and 1, 6-Diaminohexane*, *International*
252 *Journal of Pharmaceutical Science Invention*, 6 (13) (2017), 38–43.
- 253 [12] T.N.P. Huynh, *Synthèse et études des relations structure/activité quantitatives (QSAR/2D) d'analyse benzo*
254 *[c] phénanthridiniques (Université d'Angers2007)*.
- 255 [13] Gaussian 09, Revision D.01, M. J. Frisch, G. W. Trucks, H. B. Schlegel, G. E. Scuseria, M. A. Robb, J. R.
256 Cheeseman, G. Scalmani, V. Barone, B. Mennucci, G. A. Petersson, H. Nakatsuji, M. Caricato, X. Li, H. P.
257 Hratchian, A. F. Izmaylov, J. Bloino, G. Zheng, J. L. Sonnenberg, M. Hada, M. Ehara, K. Toyota, R. Fukuda,
258 J. Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, T. Vreven, J. A. Montgomery, Jr., J. E.
259 Peralta, F. Ogliaro, M. Bearpark, J. J. Heyd, E. Brothers, K. N. Kudin, V. N. Staroverov, T. Keith, R.
260 Kobayashi, J. Normand, K. Raghavachari, A. Rendell, J. C. Burant, S. S. Iyengar, J. Tomasi, M. Cossi, N.
261 Rega, J. M. Millam, M. Klene, J. E. Knox, J. B. Cross, V. Bakken, C. Adamo, J. Jaramillo, R. Gomperts, R.
262 E. Stratmann, O. Yazyev, A. J. Austin, R. Cammi, C. Pomelli, J. W. Ochterski, R. L. Martin, K. Morokuma,
263 V. G. Zakrzewski, G. A. Voth, P. Salvador, J. J. Dannenberg, S. Dapprich, A. D. Daniels, O. Farkas, J. B.
264 Foresman, J. V. Ortiz, J. Cioslowski, and D. J. Fox, Gaussian, Inc., Wallingford CT, 2013, - Google Search.
- 265 [14] P. Ayers, Parr RG, *J. Am. Chem. Soc.*, 2000 (2000), 122–2010.
- 266 [15] F. de Proft and P. Geerlings, *Conceptual and computational DFT in the study of aromaticity*, *Chemical*
267 *reviews*, 101 (5) (2001), 1451–1464.
- 268 [16] F. de Proft, J.M.L. Martin and P. Geerlings, *On the performance of density functional methods for describing*
269 *atomic populations, dipole moments and infrared intensities*, *Chemical Physics Letters*, 250 (3-4) (1996),
270 393–401.
- 271 [17] J.R. Pliego Jr, *Thermodynamic cycles and the calculation of pKa*, *Chemical Physics Letters*, 367 (1-2) (2003),
272 145–149.
- 273 [18] R. Franke, *Theoretical drug design methods* (Elsevier Science Ltd1984).

- 274 [19] K.N. N'guessan, M.G.-R. Koné, K. Bamba, O.W. Patrice and N. Ziao, Quantitative structure anti-cancer
275 activity relationship (QSAR) of a series of ruthenium complex azopyridine by the density functional theory
276 (DFT) method, *Computational Molecular Bioscience*, 7 (02) (2017), 19.
- 277 [20] XLSTAT version 2016.5.03- Google Search, Copyright Addinsoft 1995-2014 XLSTAT and Addinsoft are
278 Registered Trademarks of Addinsoft. 2016, <https://www.xlstat.com>
- 279 [21] T. Koopmans, Über die Zuordnung von Wellenfunktionen und Eigenwerten zu den einzelnen Elektronen
280 eines Atoms, *Physica*, 1 (1-6) (1934), 104–113.
- 281 [22] Logiciel libre Molinspiration Cheminformatics, <http://www.molinspiration.com>. Accession en (02 May 2019).
- 282 [23] B. Lee and F.M. Richards, The interpretation of protein structures, *Journal of molecular biology*, 55 (3)
283 (1971), 379-IN4.
- 284 [24] A. Shrake and J.A. Rupley, Environment and exposure to solvent of protein atoms. Lysozyme and insulin,
285 *Journal of molecular biology*, 79 (2) (1973), 351–371.
- 286 [25] V.V. Nalimov, *The application of mathematical statistics to chemical analysis* (Elsevier2014).
- 287 [26] A.R. Katritzky, V.S. Lobanov and M. Karelson, CODESSA, University of Florida, Gainesville, FL (1994).
- 288 [27] K. Roy, S. Kar and R.N. Das, *Understanding the basics of QSAR for applications in pharmaceutical sciences*
289 and risk assessment (Academic press2015).
- 290 [28] M. Larif, A. Adad, R. Hmamouchi, A.I. Taghki, A. Soulaymani, A. Elmidaoui, M. Bouachrine and T.
291 Lakhliifi, Biological activities of triazine derivatives. Combining DFT and QSAR results, *Arabian Journal of*
292 *Chemistry*, 10 (2017), S946-S955.
- 293 [29] S. Karabulut, N. Sizochenko, A. Orhan and J. Leszczynski, A DFT-based QSAR study on inhibition of
294 human dihydrofolate reductase, *Journal of molecular graphics and modelling*, 70 (2016), 23–29.
- 295 [30] G.A.F. Seber and A.J. Lee, *Linear regression analysis* (John Wiley & Sons2012).
- 296 [31] K. Asgaonkar, G. Mote and T. Chitre, QSAR and molecular docking studies of oxadiazole-ligated pyrrole
297 derivatives as enoyl-ACP (CoA) reductase inhibitors, *Scientia pharmaceutica*, 82 (1) (2013), 71–86.
- 298 [32] C. Rücker, G. Rücker and M. Meringer, γ -Randomization and its variants in QSPR/QSAR, *Journal of*
299 *chemical information and modeling*, 47 (6) (2007), 2345–2357.
- 300 [33] L. Eriksson, J. Jaworska, A.P. Worth, M.T.D. Cronin, R.M. McDowell and P. Gramatica, Methods for
301 reliability and uncertainty assessment and for applicability evaluations of classification-and regression-based
302 QSARs, *Environmental health perspectives*, 111 (10) (2003), 1361–1375.
- 303 [34] A. Tropsha, P. Gramatica and V.K. Gombar, The importance of being earnest, *QSAR & Combinatorial*
304 *Science*, 22 (1) (2003), 69–77.
- 305 [35] O. Ouattara, A. Thomas Sopi, M.G.-R. Koné, K. Bamba and N. Ziao, Can Empirical Descriptors Reliably
306 Predict Molecular Lipophilicity? A QSPR Study Investigation, *Int. Journal of Engineering Research and*
307 *Application*, 7 (15) (2017), 50–56.
- 308 [36] A. Golbraikh and A. Tropsha, Beware of $q^2!$, *Journal of molecular graphics and modelling*, 20 (4) (2002),
309 269–276.
- 310